Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell Cancer.
Kyung-Pil KoShengzhe ZhangYuanjian HuangBongjun KimGengyi ZouSohee JunJie ZhangCecilia MartinKaren J DunbarGizem EfeAnil K RustgiHaiyang ZhangHiroshi NakagawaJae-Il ParkPublished in: bioRxiv : the preprint server for biology (2023)
Despite the promising outcomes of immune checkpoint blockade (ICB), resistance to ICB presents a new challenge. Therefore, selecting patients for specific ICB applications is crucial for maximizing therapeutic efficacy. Herein we curated 69 human esophageal squamous cell cancer (ESCC) patients’ tumor microenvironment (TME) single-cell transcriptomic datasets to subtype ESCC. Integrative analyses of the cellular network transcriptional signatures of T cells, myeloid cells, and fibroblasts define distinct ESCC subtypes characterized by T cell exhaustion, Interferon (IFN) a/b signaling, TIGIT enrichment, and specific marker genes. Furthermore, this approach classifies ESCC patients into ICB responders and non-responders, as validated by liquid biopsy single-cell transcriptomics. Our study stratifies ESCC patients based on TME transcriptional network, providing novel insights into tumor niche remodeling and predicting ICB responses in ESCC patients.
Keyphrases
- skeletal muscle
- insulin resistance
- end stage renal disease
- single cell
- ejection fraction
- newly diagnosed
- squamous cell
- chronic kidney disease
- gene expression
- peritoneal dialysis
- squamous cell carcinoma
- type diabetes
- dendritic cells
- bone marrow
- metabolic syndrome
- acute myeloid leukemia
- high throughput
- dna methylation
- cell death
- cell proliferation
- young adults
- induced apoptosis
- endoplasmic reticulum stress
- lymph node metastasis
- cell cycle arrest
- induced pluripotent stem cells